It has been shown that MRD-directed IFN-α treatment was able to significantly decrease the risk of cumulative incidence of relapse and improve survival in MRD-positive AML patients post-HCT, compared to MRD patients with no intervention (77, 78). This evidence concerns the gene IFNA2 and acute myeloid leukemia.